Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ralinepag in pulmonary arterial hypertension
NL-OMON54562Phase 3Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Ralinepag with Placebo (2 arms). Primary endpoint: Time to first adjudicated protocol-defined clinical worsening event. Started Jan 2021; status: recruiting.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON54562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54562.